{"id":"dapagliflozin-metformin","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Genital mycotic infections"},{"rate":"3-8","effect":"Urinary tract infections"},{"rate":"5-15","effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":"2-5","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Polyuria"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination leverages two complementary mechanisms: dapagliflozin works by blocking SGLT2 in the proximal tubule, allowing filtered glucose to be excreted in urine rather than reabsorbed, thereby lowering blood glucose independently of insulin. Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity through AMPK activation. Together, they provide additive glycemic control with distinct mechanisms of action.","oneSentence":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:37.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT07120828","phase":"PHASE4","title":"The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity","status":"COMPLETED","sponsor":"Erbil Polytechnic University","startDate":"2025-07-15","conditions":"Type 2 Diabetes, Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)","enrollment":260},{"nctId":"NCT03982381","phase":"PHASE4","title":"SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2019-09-05","conditions":"Type 2 Diabetes","enrollment":2067},{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07399470","phase":"PHASE1","title":"A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"LG Chem","startDate":"2026-01-09","conditions":"Healthy Volunteers, Fasting Conditions","enrollment":58},{"nctId":"NCT07396844","phase":"PHASE1","title":"The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"LG Chem","startDate":"2026-07-01","conditions":"Healthy, Fasting, Fed","enrollment":28},{"nctId":"NCT07363707","phase":"PHASE4","title":"A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2023-05-01","conditions":"NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":108},{"nctId":"NCT07379333","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"NOT_YET_RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2026-02","conditions":"Type 2 Diabetes","enrollment":118},{"nctId":"NCT07303556","phase":"NA","title":"Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nazarbayev University","startDate":"2024-12-18","conditions":"Heart Failure, Diabete Type 2, Arterial Hypertension","enrollment":120},{"nctId":"NCT07342764","phase":"PHASE4","title":"Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2026-04","conditions":"Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":120},{"nctId":"NCT07333742","phase":"PHASE1","title":"A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal","status":"COMPLETED","sponsor":"LG Chem","startDate":"2025-09-29","conditions":"Fed Conditions, Healthy Volunteer","enrollment":50},{"nctId":"NCT06528405","phase":"PHASE2","title":"The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Acute Kidney Injury","enrollment":264},{"nctId":"NCT06415773","phase":"PHASE3","title":"Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2024-06-04","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":367},{"nctId":"NCT07311551","phase":"PHASE4","title":"A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)","status":"NOT_YET_RECRUITING","sponsor":"Bhavya Bhavya, MD","startDate":"2025-12-24","conditions":"Type 2 Diabetes","enrollment":112},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07254572","phase":"PHASE4","title":"Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2025-07-10","conditions":"Coronary Artery Disease, PreDiabetes","enrollment":300},{"nctId":"NCT06327815","phase":"PHASE4","title":"Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-03-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":633},{"nctId":"NCT06192108","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-10","conditions":"Type 2 Diabetes","enrollment":962},{"nctId":"NCT03968224","phase":"PHASE2, PHASE3","title":"Effectiveness of Dapagliflozin for Weight Loss","status":"COMPLETED","sponsor":"Centro Medico Nacional Siglo XXI IMSS","startDate":"2018-08-04","conditions":"PreDiabetes, Obesity, Morbid, Diabetes Mellitus, Type 2","enrollment":160},{"nctId":"NCT07026968","phase":"PHASE3","title":"A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-06-20","conditions":"Type 2 Diabetes","enrollment":815},{"nctId":"NCT07193069","phase":"","title":"Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning","status":"RECRUITING","sponsor":"Centre Hospitalier de Saint-Denis","startDate":"2025-04-11","conditions":"Drug Overdose, Metformin, Dapagliflozin","enrollment":50},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT02969798","phase":"NA","title":"Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-01-01","conditions":"Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)","enrollment":700},{"nctId":"NCT07083401","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fed)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-05","conditions":"Diabete Mellitus","enrollment":40},{"nctId":"NCT07083388","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fasting)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-03","conditions":"Diabetes Mellitus","enrollment":52},{"nctId":"NCT07082114","phase":"PHASE3","title":"A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-07-14","conditions":"Type 2 Diabetes","enrollment":800},{"nctId":"NCT07077525","phase":"PHASE4","title":"Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-06-01","conditions":"Type 2 Diabetes","enrollment":196},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT04451837","phase":"PHASE2","title":"Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2020-09-10","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT07033585","phase":"PHASE2, PHASE3","title":"Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-06-15","conditions":"Type 2 Diabetes","enrollment":600},{"nctId":"NCT07044765","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study","status":"NOT_YET_RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2025-08","conditions":"Type2 Diabetes Mellitus","enrollment":32},{"nctId":"NCT07034781","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2025-08","conditions":"Type2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT07019012","phase":"PHASE4","title":"Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-07-30","conditions":"T2DM","enrollment":170},{"nctId":"NCT04090580","phase":"PHASE3","title":"Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2019-10-27","conditions":"Type 2 Diabetes","enrollment":88},{"nctId":"NCT05998837","phase":"PHASE2, PHASE3","title":"GLUcose Transport and REnalPROtection in Chronic Kidney Disease","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2021-04-13","conditions":"Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension","enrollment":34},{"nctId":"NCT06000462","phase":"PHASE4","title":"The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oman Ministry of Health","startDate":"2024-04-22","conditions":"Obesity, Dapagliflozin Adverse Reaction, Weight Loss","enrollment":150},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT05743907","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-04-25","conditions":"Diabetes Mellitus","enrollment":231},{"nctId":"NCT02695121","phase":"","title":"Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-01","conditions":"Breast Cancer, Bladder Cancer","enrollment":2133575},{"nctId":"NCT06589765","phase":"PHASE3","title":"A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-09-27","conditions":"Type 2 Diabetes","enrollment":800},{"nctId":"NCT05345327","phase":"PHASE3","title":"SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes","status":"RECRUITING","sponsor":"The George Institute","startDate":"2023-01-01","conditions":"Type 2 Diabetes","enrollment":994},{"nctId":"NCT06576375","phase":"PHASE3","title":"Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome","status":"RECRUITING","sponsor":"Future University in Egypt","startDate":"2024-09-02","conditions":"Polycystic Ovary Syndrome","enrollment":70},{"nctId":"NCT04899349","phase":"PHASE2","title":"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-04-06","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT06611904","phase":"NA","title":"The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Attikon Hospital","startDate":"2018-02-01","conditions":"Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness","enrollment":60},{"nctId":"NCT05833958","phase":"PHASE2","title":"Polypill Versus Metformin in New Onset Type 2 Diabetes","status":"WITHDRAWN","sponsor":"George Medicines PTY Limited","startDate":"2024-09","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT06405178","phase":"PHASE3","title":"Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-09-30","conditions":"Polycystic Ovary","enrollment":500},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06370247","phase":"NA","title":"First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-04-25","conditions":"SGLT2 Inhibitors, First Time Use, Type2 Diabetes, Fasting in Ramadan","enrollment":60},{"nctId":"NCT05505994","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-09-28","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders","enrollment":340},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT06147518","phase":"NA","title":"To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-20","conditions":"Compensated Cirrhosis, Decompensated Cirrhosis","enrollment":240},{"nctId":"NCT02911792","phase":"PHASE4","title":"Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT06127433","phase":"PHASE4","title":"The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-07","conditions":"Insulin Pump，Continuous Glucose Monitoring Technology","enrollment":210},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05601336","phase":"PHASE3","title":"of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2022-01-15","conditions":"PCO","enrollment":200},{"nctId":"NCT04885712","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-05-28","conditions":"Type2 Diabetes","enrollment":378},{"nctId":"NCT03710460","phase":"PHASE4","title":"Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity","status":"UNKNOWN","sponsor":"University of Guadalajara","startDate":"2019-07-30","conditions":"Obesity","enrollment":33},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT03842267","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)","status":"COMPLETED","sponsor":"LG Chem","startDate":"2019-05-13","conditions":"Diabetes Mellitus, Type 2","enrollment":315},{"nctId":"NCT02919345","phase":"PHASE4","title":"Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease, Carotid Artery Diseases","enrollment":98},{"nctId":"NCT00643851","phase":"PHASE3","title":"An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":994},{"nctId":"NCT03714594","phase":"PHASE2","title":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2018-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT04634500","phase":"PHASE3","title":"The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-11-18","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":200},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT05477017","phase":"","title":"Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"University of Milan","startDate":"2022-09","conditions":"Type2Diabetes","enrollment":800},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT03826641","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-02-01","conditions":"Healthy","enrollment":85},{"nctId":"NCT05440591","phase":"PHASE4","title":"Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2019-04-01","conditions":"Diabetes","enrollment":150},{"nctId":"NCT05162690","phase":"PHASE2, PHASE3","title":"Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-05-01","conditions":"Diabetic Peripheral Neuropathy","enrollment":40},{"nctId":"NCT05226897","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients","status":"UNKNOWN","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2021-07-12","conditions":"Type 2 Diabetes","enrollment":256},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT04856007","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-12","conditions":"Healthy Volunteer","enrollment":80},{"nctId":"NCT05296044","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"UNKNOWN","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2022-04-05","conditions":"Type 2 Diabetes Mellitus","enrollment":245},{"nctId":"NCT04356742","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-05-26","conditions":"Type 2 Diabetes","enrollment":198},{"nctId":"NCT05262257","phase":"EARLY_PHASE1","title":"Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-04-01","conditions":"Type2 Diabetes","enrollment":120},{"nctId":"NCT05101135","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"UNKNOWN","sponsor":"Jeil Pharmaceutical Co., Ltd.","startDate":"2021-11-17","conditions":"Type 2 Diabetes Mellitus","enrollment":256},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT05159882","phase":"PHASE3","title":"Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM","status":"UNKNOWN","sponsor":"Newsoara Biopharma Co., Ltd.","startDate":"2021-04-15","conditions":"T2DM","enrollment":390},{"nctId":"NCT04170998","phase":"PHASE3","title":"Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-01-02","conditions":"Type2 Diabetes","enrollment":283},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT04796428","phase":"PHASE4","title":"GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial","status":"UNKNOWN","sponsor":"Center for Outcomes Research and Clinical Epidemiology, Italy","startDate":"2021-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":1167},{"nctId":"NCT02235298","phase":"PHASE4","title":"Dapagliflozin Effects on Epicardial Fat","status":"COMPLETED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT02635386","phase":"PHASE3","title":"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Woman's","startDate":"2016-03-22","conditions":"Polycystic Ovary Syndrome, Obesity","enrollment":119},{"nctId":"NCT04706637","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin","status":"UNKNOWN","sponsor":"Kyung Hee University Hospital at Gangdong","startDate":"2021-02-01","conditions":"Bone Diseases, Metabolic, Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT02561130","phase":"PHASE4","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":154},{"nctId":"NCT03917758","phase":"NA","title":"Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2018-10-10","conditions":"Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes","enrollment":30},{"nctId":"NCT03038789","phase":"","title":"XIGDUO Extended Release (XR) Post Marketing Surveillance","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-04-20","conditions":"Adult Patients With Type 2 Diabetes Mellitus","enrollment":623},{"nctId":"NCT02682563","phase":"PHASE4","title":"Renoprotective Effects of Dapagliflozin in Type 2 Diabetes","status":"COMPLETED","sponsor":"M.H.H. Kramer","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2, Diabetic Nephropathies","enrollment":44},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT02597049","phase":"PHASE3","title":"A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":424},{"nctId":"NCT03982238","phase":"PHASE4","title":"Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Majianhua","startDate":"2019-06-15","conditions":"Type 2 Diabetes","enrollment":74},{"nctId":"NCT03419624","phase":"PHASE3","title":"The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2018-02-19","conditions":"Obesity, Diabetes Mellitus, Type 2","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xigduo","Group 1"],"phase":"phase_3","status":"active","brandName":"Dapagliflozin/Metformin","genericName":"Dapagliflozin/Metformin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}